Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17100764 | 0.91 | PKM (0.49) | TSHRMEN1KMT2AHSD11B1PKM | |
| SCHEMBL17100821 | 0.90 | HSD11B1 (0.46) | TSHRMEN1KMT2AHSD11B1PKM | |
| SCHEMBL17100679 | 0.86 | PKM (0.55) | TSHRKMT2AHSD11B1PKMGBA1 | |
| SCHEMBL17100810 | 0.83 | GBA1 (0.41) | MEN1KMT2AHSD11B1PKMGBA1 | |
| SCHEMBL17100665 | 0.82 | HSD11B1 (0.49) | TSHRMEN1KMT2AHSD11B1PKM | |
| SCHEMBL17100887 | 0.81 | HSD11B1 (0.41) | TSHRMEN1KMT2AHSD11B1PKM | |
| SCHEMBL17100720 | 0.79 | TSHR (0.47) | TSHRMEN1KMT2AHSD11B1PKM | |
| SCHEMBL17100667 | 0.78 | HSD11B1 (0.50) | TSHRMEN1KMT2AHSD11B1PKM | |
| SCHEMBL17100892 | 0.77 | TSHR (0.45) | TSHRMEN1KMT2AHSD11B1PKM | |
| SCHEMBL17100797 | 0.77 | HSD11B1 (0.49) | TSHRMEN1KMT2AHSD11B1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | claimed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | claimed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | claimed |
| EP-3119774-A1 | OXADIAZOLE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | claimed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| EP-3119774-A1 | OXADIAZOLE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562869-B2 | Oxadiazole compounds | OXA1L, PSEN1, MAPT | TSHR 1833/4885MEN1 2665/4885KMT2A 4820/4885 |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | TSHR 1962/4885MEN1 2837/4885KMT2A 4819/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | TSHR 1833/4885MEN1 2665/4885KMT2A 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.